2010
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. European Journal Of Cancer 2010, 46: 944-953. PMID: 20060709, DOI: 10.1016/j.ejca.2009.12.019.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerTrop-2 overexpressionTrop-2 expressionOverall survivalPrognostic factorsProtein overexpressionTrop-2 protein expressionMultivariate Cox regression analysisConventional clinicopathological featuresPresence of ascitesCox regression analysisLymph node metastasisOvarian carcinoma patientsPoor overall survivalIndependent prognostic markerNovel prognostic factorUnivariate survival analysisAggressive malignant phenotypeImmunotherapeutic strategiesShort-term cultureCarcinoma patientsClinical courseNode metastasisClinicopathological featuresPrognostic significance
2004
Immunological treatment of ovarian cancer
Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Current Opinion In Obstetrics & Gynecology 2004, 16: 87-92. PMID: 15128013, DOI: 10.1097/00001703-200402000-00015.Peer-Reviewed Original ResearchConceptsImmunological treatmentOvarian cancerAntibody responseClinical trialsAntigen-specific helper T lymphocytesAdvanced stage ovarian cancerHuman anti-mouse antibody responseAnti-mouse antibody responseImportant target antigenNovel immunological treatmentsDendritic cell vaccinationNovel immunotherapeutic strategiesT cell immunityT lymphocyte responsesStage ovarian cancerHelper T lymphocytesRecent clinical trialsOvarian tumor antigenElicit antibody responsesMouse monoclonal antibodyEvasion of immunityTime of treatmentCell vaccinationRecurrent diseaseImmunotherapeutic strategies
2002
Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD, Bellone S, Underwood LJ, O'Brien TJ, Ravaggi A, Pecorelli S, Cannon MJ. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Obstetrics And Gynecology 2002, 54: 133-44. PMID: 12032451.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, NeoplasmCancer VaccinesChildClinical Trials as TopicCombined Modality TherapyDendritic CellsFemaleGPI-Linked ProteinsHumansImmunohistochemistryImmunotherapyKallikreinsMatrix Metalloproteinase 7Membrane ProteinsNeoplasm MetastasisOvarian NeoplasmsSerine EndopeptidasesT-Lymphocytes, CytotoxicTumor Cells, CulturedConceptsTumor antigensOvarian cancerChemotherapy-resistant ovarian cancerOvarian tumor-associated antigensDendritic cell-based immunotherapyTumor-specific immune responsesEffective tumor antigensTherapeutic DC vaccinationNovel immunotherapeutic strategiesStandard treatment modalityCell-based immunotherapyOvarian tumor antigenSpecific immune responseTumor-associated antigensPotential of DCDC vaccinationImmunotherapeutic strategiesDendritic cellsCancer vaccinationCancer patientsGynecologic oncologyTreatment modalitiesNatural adjuvantImmune responseAntigen preparations